Latest Neuroendocrine tumor Stories
THE WOODLANDS, Texas, Aug. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc.
A targeted and personalized medicine approach to lung cancer. Somerville, MA (PRWEB) August 01, 2011 Andarix Pharmaceuticals, a clinical stage company, announces the appointment of leading clinical oncology experts to its clinical advisory board.
A new treatment option may soon be available for children with neuroblastoma.
MANHATTAN BEACH, Calif., May 20, 2011 /PRNewswire/ -- The Pfizer drug SutentÂ® (sunitinib) has been approved for the treatment of advanced pancreatic neuroendocrine tumors by the U.S. Food and Drug Administration (FDA).
SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S.
MANHATTAN BEACH, Calif., May 6, 2011 /PRNewswire/ -- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug AfinitorÂ® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.
SILVER SPRING, Md., May 6, 2011 /PRNewswire-USNewswire/ -- On Thursday, the U.S.
EAST HANOVER, N.J., May 5, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved AfinitorÂ® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4).
- To give a box on the ear to.